Owens & Minor, Inc. (OMI) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Group 1 - The sale of the P&HS business is now definitive, although it still requires closure and is subject to FTC review, indicating increased certainty around the transaction [1] - The company has transitioned to a pure-play Patient Direct business, which will allow for a more focused operational strategy and capital allocation [2] - With the constraints from the P&HS business removed, the company can now invest more aggressively in technology, sales, and product categories to accelerate growth [2]